Results 171 to 180 of about 66,382 (184)

Lipid Effects of Psychiatric Medications

Current Atherosclerosis Reports, 2012
J. Watanabe, Yutaro Suzuki, T. Someya
semanticscholar   +1 more source

Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)

Expert Opinion on Investigational Drugs, 2018
P. Thompson, J. Burger
semanticscholar   +1 more source

Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents

CNS Drugs, 2018
M. Jann, S. Penzak
semanticscholar   +1 more source

Subject index

, 2003

semanticscholar   +1 more source

A population‐based study of the comparative effectiveness of second‐generation antipsychotics vs older antimanic agents in bipolar disorder

Bipolar Disorders, 2016
M. Bauer, Christopher J. Miller, Mingfei Li, L. Bajor, Austin Lee   +4 more
semanticscholar   +1 more source

Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria

BioDrugs, 2020
B. Fattizzo, A. Kulasekararaj
semanticscholar   +1 more source

New anti-HER2 agents: from second-generation tyrosine kinases inhibitors to bifunctional antibodies

Current Opinion in Oncology, 2017
J. Gligorov, S. Richard, V. Todorovic
semanticscholar   +1 more source

Resistance to second-generation androgen receptor antagonists in prostate cancer

Nature reviews. Urology, 2021
Keith T. Schmidt, A. Huitema, C. Chau, W. Figg   +3 more
semanticscholar   +1 more source

The Ascendancy of Second-Generation Antipsychotics as Frontline Antimanic Agents

Journal of Clinical Psychopharmacology, 2015
Christopher J. Miller, Mingfei Li, R. Penfold, Austin Lee, Eric G. Smith, S. Nordberg, D. Osser, L. Bajor, Fang Zhang, M. Bauer   +9 more
semanticscholar   +1 more source

Prevalence of the Metabolic Syndrome in Schizophrenic Patients Receiving Second-Generation Antipsychotic Agents—A Cross-Sectional Study

Journal of pharmacy and practice, 2012
U. Kagal, S. Torgal, N. Patil, A. Malleshappa   +3 more
semanticscholar   +1 more source